Fabrice Beretta is a pharmaceutical product development strategist and an expert in operational excellence. He has dedicated over fifteen years to developing and commercializing precision medicine products for cancer and rare diseases at Genentech, BioMarin, and Ultragenyx. He has also led programs to accelerate bench-to-bedside innovations at UCSF and develop FDA-approved botanical drugs sourced sustainably from the Amazon rainforest at Jaguar Health. Additionally, Fabrice served on the Board of the Zen Hospice Project in San Francisco, contributing to the redesign of palliative care.

With a background in chemical engineering, business administration, public health, and data science, Fabrice thrives at leading cross-functional teams integrating research, regulatory knowledge, clinical development, and commercial expertise to address complex health challenges. As an Advisor to Delphi, a premier psychedelic consultancy, he is passionate about advancing precision psychiatry.

Outside of his professional endeavors, Fabrice enjoys nature and athletic activities. You can find him surfing challenging waves around the world, road cycling through Alpine mountain ranges, diving with sharks, or exploring remote areas of the Amazon rainforest.

3. Accomplishments:

Built supply capabilities from the ground up to launch a new probiotic line

“CEO” of pharmaceutical asset development teams for 15+ years

Took 2 rare disease drugs to clinical trials at Biomarin

Led Medical Teams to Launch 2 rare disease drugs at Ultragenyx

Operated 2 Corporate internal innovation incubators at Genentech and UCSF to enable precision medicine, including AI/ML and Companion Diagnostic capabilities like Flatiron and Foundation Medicines